DNLI - Denali Therapeutics Inc.
After hours:
Chart Events
Williams %R
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 30.46 |
| Open | 30.51 |
| Bid | 29.50 x 800 |
| Ask | 30.49 x 800 |
| Day's Range | 30.11 - 30.96 |
| 52 Week Range | 20.76 - 39.43 |
| Volume | |
| Avg. Volume | 750,444 |
| Market Cap | 4.186B |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.83 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.50 |
Fair Value
Related Research
BenzingaBiogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
In its ongoing R&D reorganization, Biogen Inc (NASDAQ: BIIB) will discontinue a Phase 3 program evaluating BIIB122 as a treatment for patients with Parkinson’s disease related to LRRK2 mutations with partner Denali Therapeutics Inc (NASDAQ: DNLI). Before the planned revisions, the BIIB122 development program encompassed the following: The Phase 2b LUMA study in participants with early-stage Parkinson’s disease commenced in May 2022. The Phase 3 LIGHTHOUSE study in participants with Parkinson’s d
Simply Wall St.Denali Therapeutics (NASDAQ:DNLI) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
PR NewswireFlagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
Flagship Pioneering, the bioplatform innovation company, today announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics. Two years into development, Flagship has made an initial commitment of $50 million to advance Metaphore's MIMiC™ platform and build its pipeline for patients with autoimmune, metabolic, or oncology indications.
Motley FoolWhy Shares of Denali Therapeutics Are Up Monday
Shares of Denali Therapeutics (NASDAQ: DNLI) were up more than 14% Monday afternoon. The company reported first-quarter earnings a week ago, and three analysts recently maintained their buy ratings on the clinical-stage biotech company, which focuses on therapies that cross the blood-brain barrier to treat neurodegenerative and lysosomal storage diseases. Analysts Andrew Fein of H.C. Wainwright, Berenberg Bank's Caroline Palomeque, and Wedbush's Laura Chio all maintained their buy ratings for Denaii, despite a so-so earnings report early last week.
ZacksDenali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
ZacksDenali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.68% and 15.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireDenali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2023, and provided business highlights. “In the first quarter, we continued to make significant progress across our b
- Simply Wall St.
Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 40% Undervaluation?
Key Insights Denali Therapeutics' estimated fair value is US$43.39 based on 2 Stage Free Cash Flow to Equity Denali...
ZacksEarnings Preview: Arcus Biosciences, Inc. (RCUS) Q1 Earnings Expected to Decline
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksDenali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Denali Therapeutics Inc. (DNLI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Denali Therapeutics' (NASDAQ:DNLI) investors will be pleased with their 28% return over the last five years
While Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders are probably generally happy, the stock hasn't had...
- GlobeNewswire
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagementCAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV):Amyloid beta program (ATV:Aβ). Accumulation of Aβ plaque in the brain is a defining feature of
- GlobeNewswire
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers associated with the integrated stress response (ISR)Clinical pharmacokinetic and ISR pharmacodynamic data, along with preclinical data, are consistent with extensive CNS distribution and support once-daily dosingInitiation of DNL343 regimen in the Phase 2/3 HEALEY ALS Platform Trial is expected in mid 2023 SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics
ZacksY-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains?
Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
ZacksWhy Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report?
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically
Market forces rained on the parade of Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders today, when the analysts...
ZacksDenali (DNLI) Q4 Earnings Beat Estimates, Pipeline in Focus
Denali (DNLI) reports better-than-expected results for the fourth quarter and full-year 2022, as it beats both earnings and revenue estimates.
ZacksDenali Therapeutics Inc. (DNLI) Reports Q4 Loss, Tops Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 3.85% and 28.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter and year ended December 31, 2022, and provided business highlights. “2022 was an important year for Denali, marked by transition to
BenzingaDenali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome Study
Denali Therapeutics Inc (NASDAQ: DNLI) announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 in children with MPS II (Hunter syndrome), including data from additional participants and up to 104 weeks of treatment. Over 49 weeks of DNL310 treatment in the Phase 1/2 study, positive changes across measures of exploratory clinical outcomes, including VABS-II (adaptive behavior) and BSID-III (cognitive capabilities) scores and global impression scales, were o
- GlobeNewswire
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
Over 49 weeks of DNL310 (ETV:IDS) treatment in the Phase 1/2 study, positive changes across measures of exploratory clinical outcomes including VABS-II (adaptive behavior) and BSID-III (cognitive capabilities) scores and global impression scales were observedInterim Phase 1/2 data also suggest that DNL310 improves hearing, as assessed by auditory brainstem response testing Additional biomarker data out to 49 weeks continue to demonstrate that DNL310 enables rapid and sustained normalization of C
ZacksHeska (HSKA) Earnings Expected to Grow: Should You Buy?
Heska (HSKA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEarnings Preview: Denali Therapeutics Inc. (DNLI) Q4 Earnings Expected to Decline
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced upcoming presentations from Enzyme Transport Vehicle (ETV) development programs, DNL310 (ETV:IDS) and DNL126 (ETV:SGSH), to be given at the 19th Annual WORLDSymposium™, which wi
ZacksDenali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains?
Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.